A large number of studies have confirmed that [3, 4] epidermal growth factor receptor tyrosine kinase inhibitors (EGFR tyrosine kinase inhibitors, EGFR-TKIs) are effective molecular-targeted therapy drugs for patients with advanced NSCLC and they have been widely used in clinical practice. Here, EGFR is linked to non-small cell lung carcinoma.